Maximus (NYSE:MMS) Upgraded by Wall Street Zen to Buy Rating

Maximus (NYSE:MMS - Get Free Report) was upgraded by Wall Street Zen from a "hold" rating to a "buy" rating in a research report issued on Sunday.Other research analysts also recently issued research reports about the stock. Weiss Ratings reiterated a "buy (b-)" rating on shares of Maximus in a report on Monday, December 29th. Zacks Research upgraded Maximus from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, December 30th. One research analyst has rated the stock with a Strong Buy rating and one has assigned a Buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Strong Buy".View Our Latest Analysis on MMSMaximus Trading Up 1.4%Shares of MMS stock opened at $74.75 on Friday. The company has a quick ratio of 2.34, a current ratio of 2.34 and a debt-to-equity ratio of 0.88. The stock has a 50-day simple moving average of $89.09 and a 200 day simple moving average of $86.58. Maximus has a fifty-two week low of $63.77 and a fifty-two week high of $100.00. The stock has a market capitalization of $4.08 billion, a P/E ratio of 11.38 and a beta of 0.57. Maximus (NYSE:MMS - Get Free Report) last released its earnings results on Thursday, February 5th. The health services provider reported $1.85 earnings per share for the quarter, topping the consensus estimate of $1.84 by $0.01. The business had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $1.37 billion. Maximus had a net margin of 6.92% and a return on equity of 25.30%. The firm's quarterly revenue was down 4.1% compared to the same quarter last year. During the same period last year, the firm posted $1.61 earnings per share. Maximus has set its FY 2026 guidance at 8.050-8.350 EPS. On average, sell-side analysts expect that Maximus will post 6.15 earnings per share for the current fiscal year. Insider Activity at MaximusIn other Maximus news, insider Michelle F. Link sold 4,039 shares of the stock in a transaction that occurred on Wednesday, December 3rd. The shares were sold at an average price of $86.84, for a total transaction of $350,746.76. Following the transaction, the insider owned 19,542 shares in the company, valued at $1,697,027.28. This represents a 17.13% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Bruce Caswell purchased 3,175 shares of the company's stock in a transaction that occurred on Tuesday, February 10th. The stock was bought at an average cost of $78.45 per share, with a total value of $249,078.75. Following the purchase, the chief executive officer owned 328,013 shares of the company's stock, valued at $25,732,619.85. This represents a 0.98% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders bought 4,231 shares of company stock worth $329,521. Insiders own 1.80% of the company's stock. Hedge Funds Weigh In On MaximusInstitutional investors have recently added to or reduced their stakes in the stock. Royal Bank of Canada raised its position in shares of Maximus by 146.2% during the first quarter. Royal Bank of Canada now owns 19,732 shares of the health services provider's stock worth $1,345,000 after acquiring an additional 11,716 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Maximus by 0.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 34,476 shares of the health services provider's stock worth $2,351,000 after acquiring an additional 221 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Maximus by 7.0% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 180,690 shares of the health services provider's stock valued at $12,321,000 after buying an additional 11,754 shares during the last quarter. Jane Street Group LLC boosted its holdings in Maximus by 941.2% during the 1st quarter. Jane Street Group LLC now owns 98,273 shares of the health services provider's stock worth $6,701,000 after acquiring an additional 88,835 shares during the last quarter. Finally, Sivia Capital Partners LLC bought a new stake in Maximus in the 2nd quarter worth about $204,000. 97.21% of the stock is currently owned by institutional investors and hedge funds. Maximus Company Profile (Get Free Report)Maximus, Inc NYSE: MMS is a global provider of government services focused on delivering health and human services programs. The company partners with federal, state, and local agencies to administer and manage programs that support individuals and families across various stages of life. Key service areas include eligibility determination and enrollment services for Medicaid, Medicare, Children's Health Insurance Program (CHIP) and other public assistance programs, as well as call center operations, case management and program integrity solutions.Read MoreFive stocks we like better than MaximusYour Bank Account Is No Longer SafeNvidia CEO Issues Bold Tesla CallBuy this Gold Stock Before May 2026What a Former CIA Agent Knows About the Coming CollapseThe day the gold market brokeThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Maximus Right Now?Before you consider Maximus, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Maximus wasn't on the list.While Maximus currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here